GlassScriptPhysician profile
Evan C Chen
NPI 1679929574
$24,735.08
in general payments reported to CMS, 2019-2025
8 companies · $21K in 2025
The $21K reported for 2025 was more than what 88% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $66.17 · 2022: $19.02 · 2023: $2,528 · 2024: $1,405 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Honoraria: $4,715 · Travel and Lodging: $1,593 · Food and Beverage: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,381.60 |
| Honoraria | $4,715.00 |
| Travel and Lodging | $1,592.52 |
| Food and Beverage | $960.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $10,101.60 | 2025 | Winrevair |
| Syndax Pharmaceuticals, INC. | $6,210.85 | 2025 | Revuforj |
| Autolus INC | $3,718.73 | 2025 | |
| Abbvie INC. | $2,336.88 | 2023-2024 | Venclexta |
| Rigel Pharmaceuticals, INC. | $2,068.00 | 2020-2025 | Rezlidhia, Tavalisse |
| Beigene, LTD. | $280.00 | 2024 | Brukinsa |
| Pfizer INC. | $19.02 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.